Arecor Therapeutics PLC Director/PDMR Dealings (9170U)
04 August 2022 - 5:55PM
UK Regulatory
TIDMAREC
RNS Number : 9170U
Arecor Therapeutics PLC
04 August 2022
4 August 2022
Arecor Therapeutics plc
("Arecor" or the "Company" or the "Group")
Director/PDMR Dealings
and
Completion of the Acquisition of Tetris Pharma
Arecor Therapeutics plc (AIM: AREC), a globally focused
biopharmaceutical company advancing today's therapies to enable
healthier lives, announces t hat further to the Placing and
acquisition of Tetris Pharma, details of which were announced on 1
August 2022, pursuant to the Placing, the following Directors
subscribed for an aggregate amount of GBP113,271 at the Placing
Price of 300 pence per ordinary share.
Following General Admission today, the Placing and acquisition
of Tetris Pharma have now completed.
The following Directors interests in Ordinary Shares are as
follows:
N ame Placing Shares Resultant % of the
acquired shareholding Enlarged Share
following Capital
Admission
Sarah Howell ( Chief Executive
Officer) 6,666 847,072.00 2.8%
--------------- -------------- ----------------
Susan Lowther ( Chief Financial
Officer) 3,334 139,849.00 0.5%
--------------- -------------- ----------------
Andrew Richards ( Chair) 6,666 223,834.00 0.7%
--------------- -------------- ----------------
Sam Fazeli ( Non-Executive
Director) 7,756 115,708.00 0.4%
--------------- -------------- ----------------
J eremy Morgan ( Non-Executive
Director) 6,666 27,169.00 0.1%
--------------- -------------- ----------------
Christine Soden ( Non-Executive
Director) 6,667 19,167.00 0.1%
--------------- -------------- ----------------
Total 37,755
--------------- -------------- ----------------
The capitalised terms used in this announcement have the same
meanings as in the announcement published by the Company at 7.00
a.m. on 1 August 2022 unless otherwise stated.
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications
Chris Gardner, David Daley, Angela Tel: +44 (0) 20 3709 5700
Gray Email: arecor@consilium-comms.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name a) Sarah Howell
b) Susan Lowther
c) Andrew Richards
d) Sam Fazeli
e) Jeremy Morgan
f) Christine Soden
------------------------------ -------------------------------------------
Reason for the notification
2
---------------------------------------------------------------------------
a) Position/status a) Chief Executive Officer
b) Chief Financial Officer
c) Chair
d) Non-executive Director
e) Non-executive Director
f) Non-executive Director
------------------------------ -------------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------ -------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Arecor Therapeutics plc
------------------------------ -------------------------------------------
b) LEI 98450093D12I3A8DDD58
------------------------------ -------------------------------------------
Details of the transaction(s): section to be repeated
4 for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary Shares of 1p each
financial instrument,
type of instrument
Identification code ISIN: GB00BMWLM973
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------ -------------------------------------------
c) Price(s) and volume(s)
---------------------- -----------------
Price(s) Volume(s)
---------------------- -----------------
a) 300 pence a) 6,666
b) 300 pence b) 3,334
c) 300 pence c) 6,666
d) 300 pence d) 7,756
e) 300 pence e) 6,666
f) 300 pence f) 6,667
---------------------- -----------------
d) Aggregated information
- Aggregated volume 37,755
- Price 300 pence
e) Date of the transaction 4 August 2022
------------------------------ -------------------------------------------
f) Place of the transaction XLON
------------------------------ -------------------------------------------
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
.
For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBKQBPOBKKPFK
(END) Dow Jones Newswires
August 04, 2022 03:55 ET (07:55 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2023 to Apr 2024